Comparison of the extravascular penetration of the anthracyclines doxorubicin, daunorubicin, epirubicin, and mitoxantrone: A rationale for their clinical activity.

被引：0
|
作者：
Kyle, AH [1 ]
Minchinton, AI [1 ]
机构：
[1] British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada
来源：
CLINICAL CANCER RESEARCH | 2001年 / 7卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
245
引用
收藏
页码：3702S / 3702S
页数：1
相关论文
共 13 条
  • [1] Differences in accumulation of anthracyclines daunorubicin, doxorubicin and epirubicin in rat tissues revealed by immunocytochemistry
    Shin, Masashi
    Matsunaga, Hayato
    Fujiwara, Kunio
    HISTOCHEMISTRY AND CELL BIOLOGY, 2010, 133 (06) : 677 - 682
  • [2] Differences in accumulation of anthracyclines daunorubicin, doxorubicin and epirubicin in rat tissues revealed by immunocytochemistry
    Masashi Shin
    Hayato Matsunaga
    Kunio Fujiwara
    Histochemistry and Cell Biology, 2010, 133 : 677 - 682
  • [3] STABILITY AND COMPATIBILITY OF 4 ANTHRACYCLINES - DOXORUBICIN, EPIRUBICIN, DAUNORUBICIN AND PIRARUBICIN WITH PVC INFUSION BAGS
    DINE, T
    CAZIN, JC
    GRESSIER, B
    LUYCKX, M
    BRUNET, C
    CAZIN, M
    GOUDALIEZ, F
    MALLEVAIS, ML
    TORAUB, I
    PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION, 1992, 14 (06) : 365 - 369
  • [4] LIPID-PEROXIDATION OF RAT-LIVER MICROSOMES PROMOTED BY DOXORUBICIN, DAUNORUBICIN, EPIRUBICIN AND MITOXANTRONE
    VILE, G
    WINTERBURN, C
    NEW ZEALAND MEDICAL JOURNAL, 1989, 102 (861) : 50 - 50
  • [5] Chemical degradation of wastes of antineoplastic agents 2: Six anthracyclines: idarubicin, doxorubicin, epirubicin, pirarubicin, aclarubicin, and daunorubicin
    M. Castegnaro
    M. De Méo
    M. Laget
    J. Michelon
    L. Garren
    M. H. Sportouch
    S. Hansel
    International Archives of Occupational and Environmental Health, 1997, 70 : 378 - 384
  • [6] Chemical degradation of wastes of antineoplastic agents .2. Six anthracyclines: idarubicin, doxorubicin, epirubicin, pirarubicin, aclarubicin, and daunorubicin
    Castegnaro, M
    DeMeo, M
    Laget, M
    Michelon, J
    Garren, L
    Sportouch, MH
    Hansel, S
    INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, 1997, 70 (06) : 378 - 384
  • [7] EPIRUBICIN AND DOXORUBICIN - A COMPARISON OF THEIR CHARACTERISTICS, THERAPEUTIC ACTIVITY AND TOXICITY
    LAUNCHBURY, AP
    HABBOUBI, N
    CANCER TREATMENT REVIEWS, 1993, 19 (03) : 197 - 228
  • [8] Preclinical rationale, mechanisms of action, and clinical activity of anthracyclines in myeloma
    Hussein, Mohamad A.
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 : S145 - S149
  • [9] MORPHOLOGICAL-CHANGES AND CATALASE ACTIVITY IN THE HEARTS OF CD-1 MICE FOLLOWING ACUTE STARVATION OR SINGLE DOSES OF DOXORUBICIN, EPIRUBICIN OR MITOXANTRONE
    CRESCIMANNO, M
    FLANDINA, C
    RAUSA, L
    SANGUEDOLCE, R
    DALESSANDRO, N
    CHEMIOTERAPIA, 1988, 7 (01): : 53 - 59
  • [10] SAFETY ASSESSMENT OF A NEW ANTICANCER COMPOUND, MITOXANTRONE, IN BEAGLE DOGS - COMPARISON WITH DOXORUBICIN .1. CLINICAL OBSERVATIONS
    HENDERSON, BM
    DOUGHERTY, WJ
    JAMES, VC
    TILLEY, LP
    NOBLE, JF
    CANCER TREATMENT REPORTS, 1982, 66 (05): : 1139 - 1143
12